Praxis Precision net loss widens 17.7% to $83.72 million in Q2 FY26

Reuters2026/08/06 12:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Praxis Precision Medicines posted a Q2 GAAP net loss of USD 83.7 million, widening from USD 71.1 million a year earlier.
R&D expenses rose 10.16% to USD 69.4 million, driven by higher Solidus spending and personnel costs, partly offset by lower Cerebrum expenses.
G&A costs more than doubled to USD 27.5 million, on higher professional fees and personnel-related expenses.
Cash, cash equivalents and marketable securities totaled USD 1.4 billion at June 30, extending the expected operating runway into 2028.
FDA mid-cycle reviews flagged no major safety or efficacy issues for ulixacaltamide (PDUFA Jan. 29, 2027) or relutrigine (PDUFA Dec. 27, 2026).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Praxis Precision net loss widens 17.7% to $83.72 million in Q2 FY26

You may also like

Crypto prices